Login / Signup

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.

Gerasimos S FilippatosStefan D AnkerPhyllis AugustAndrew J S CoatsJames L JanuzziBoris MankovskyEllen BurgessLuis M RuilopeBertram PittPantelis A SarafidisJohn R TeerlinkChris J KapeliosMartin GebelMeike BrinkerAmer JosephAndrea LageGeorge BakrisRajiv Agarwal
Published in: European heart journal. Cardiovascular pharmacotherapy (2023)
FIDELIO-DKD and FIGARO-DKD are registered with ClinicalTrials.gov, numbers NCT02540993 and NCT02545049, respectively (funded by Bayer AG).
Keyphrases
  • type diabetes
  • cardiovascular events
  • cardiovascular disease
  • glycemic control
  • risk factors
  • insulin resistance
  • metabolic syndrome
  • coronary artery disease
  • weight loss